Nootropic peptides on TikTok: hype vs. what studies show

What did @bradyschlap actually say?

The creator, filming from what they describe as a toilet, recommends "Naislank" (N-acetyl Selank) as a daily nootropic that produces "the craziest flow state" and works like "a less intense" version of Adderall. They claim it upregulates BDNF based on animal studies, crosses the blood-brain barrier more effectively than regular Selank, and has a longer half-life than the original peptide's roughly two-minute window. They also admit upfront: "this is one of the nootropics that I've researched the least." That candor is about the most accurate thing in the video.

For readers unfamiliar with the compound, N-acetyl Selank (sometimes written N-Ac-Selank or Semax's cousin in the Russian peptide family) is a synthetic heptapeptide derived from tuftsin. It is not approved by the FDA for any indication, is not a scheduled substance in the US, and has almost no published human clinical data.

Does the science back this up?

Some of it, loosely. The BDNF claim has animal support, but calling N-acetyl Selank an Adderall substitute is a stretch the evidence does not make. The half-life comparison is directionally correct but stated with more confidence than the data warrants.

The BDNF upregulation claim traces back to preclinical Russian literature. Semenova et al. (2010, Bulletin of Experimental Biology and Medicine) found that Selank increased BDNF and BDNF mRNA expression in rat hippocampus and frontal cortex. Whether the acetylated form does the same in humans is genuinely unknown. The "better BBB crossing" claim is chemically plausible: N-acetylation generally improves lipophilicity, which can aid passive diffusion across the blood-brain barrier. But no published pharmacokinetic study in humans confirms this for N-acetyl Selank specifically. The two-minute half-life figure for regular Selank is consistent with what is cited in the Russian pharmacology literature, where the peptide was developed at the Institute of Molecular Genetics. The comparison to Adderall's mechanism is where things go off the rails. Adderall is a dopamine/norepinephrine releaser. Selank's proposed anxiolytic and nootropic effects appear to involve modulation of GABAergic tone and enkephalin metabolism (Zozulya et al., 2001, CNS Drug Reviews). These are fundamentally different mechanisms.

What did they get wrong (or right)?

They got the half-life contrast roughly right and deserve credit for citing animal studies rather than just asserting efficacy. But framing this peptide as a functional Adderall replacement is misleading, and the confidence gap between the evidence and the claims is significant.

• The "tuftsin analog" description is accurate. Selank is a synthetic analog of the immunopeptide tuftsin (Thr-Lys-Pro-Arg), extended to improve stability.
• The claim that N-acetyl Selank "lasts a lot longer" than regular Selank is plausible but unverified in published human pharmacokinetic data. This is stated as established fact when it is closer to reasonable inference.
• Comparing the subjective experience to Adderall without noting the complete mechanistic difference is irresponsible. Adderall is a Schedule II controlled substance with a well-characterized risk profile. Implying these are interchangeable by feel invites misuse of one or inappropriate substitution for the other.
• The BDNF animal data is real. Presenting it as a known human effect is an overstep.
• Zero mention of any side effects, contraindications, or the fact that this compound has no FDA approval pathway and exists in a legal gray zone for human use in the US.

What should you actually know?

N-acetyl Selank is a research compound with no approved human indication, no meaningful published human trial data, and a regulatory status that makes it legally murky to obtain in the US outside of a licensed clinical context. The "flow state" effect described is entirely anecdotal.

What the preclinical literature does suggest is interesting: anxiolytic activity without sedation, possible BDNF modulation, and a low apparent toxicity profile in animal models. Zozulya et al. (2001) described Selank as showing anxiolytic activity comparable to benzodiazepines in animal models without the accompanying sedation or withdrawal issues. That is worth noting, but it is not a human clinical result. If you are considering any peptide for cognitive or anxiety-related purposes through a regulated telehealth platform, the relevant questions are: Is there physician oversight? Is the compound sourced from a licensed compounding pharmacy? Is your specific health context part of the conversation? A TikTok filmed on a toilet does not meet that bar, regardless of how enthusiastic the presenter is.

Is comparing this to Adderall fair or safe?

No. This comparison should be rejected directly. It conflates a Schedule II stimulant with a poorly characterized research peptide, implies therapeutic equivalence where none has been established, and could influence people managing ADHD to make dangerous substitution decisions without medical guidance.

The mechanisms are different, the risk profiles are different, and the regulatory contexts are entirely different. If the creator had said "I personally find this gives me a focus-like sensation," that is an anecdote. Saying it is "perfect" for people who "like the flow state" from Adderall implies a clinical comparison that no published data supports. That framing crosses a line worth naming plainly.